Powered by

GNW: Santhera enters into agreement to acquire option from Idorsia for

Nov 20, 2018 - AWP OTS (Original Text Service)

exclusive sub-license of first-in-class dissociative steroid vamorolone

* Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase 2b study ongoing

* Vamorolone has the potential to become standard of care in young patients with DMD

* Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages

* Idorsia to become ...